Ben is a global biopharma business development professional who has been strategic advisor to leading companies, institutions and start-ups. Ben has run Nexanova since 2009 and is also Partner at Novatio Ventures, a Canadian life sciences investment firm. In addition to consulting services, Ben has provided interim management at various UK, Chinese and US biotech companies, and recently ran business development for a U.S. technology accelerator, ACTUS Biotechnologies, where he played an integral role in strategic partnering for certain transdermal and tumor-targeting technologies licensed from UCSB and Sanford Burnham by its portfolio companies, Convoy Therapeutics and EnduRx Pharmaceuticals. Ben has worked on over 40 other projects covering oncology, cardiovascular disease, neurology, dermatology and infectious diseases for leading bio-pharma clients, including Debiopharm, Green Cross, and Samyang Pharmaceutical. He has also worked closely with universities and their spin-off companies in Hong Kong and Korea, including HKUST, CUHK, SNU, and Yonsei.

 Pharmacy and Cardiology